|Bid||7.03 x 800|
|Ask||9.00 x 900|
|Day's Range||7.03 - 7.56|
|52 Week Range||5.20 - 20.40|
|Beta (3Y Monthly)||3.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 26, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.33|
Idera (IDRA) delivered earnings and revenue surprises of 17.86% and -93.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Exton, Pennsylvania-based company said it had a loss of 43 cents. Losses, adjusted for gains related to mergers and acquisitions, were 46 cents per share. The results surpassed ...
– Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 –– Cash runway into first quarter of 2020 – EXTON, Pa., Nov. 06, 2018 -- Idera.
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs, today presented data from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*) at the 2018 European Society for Medical Oncology (ESMO) Congress. The poster, which was selected for a poster discussion session, highlighted additional analyses of data for 21 patients for whom efficacy and safety analysis were originally presented at the 2018 American Society of Clinical Oncology Annual Meeting this past June (data cut-off May 9th).
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Idera Pharmaceuticals Inc (NASDAQ:IDRA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is IDRARead More...
Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that Howard Pien joined its Board of Directors, effective September 18, 2018. Mr. Pien has worked in the pharmaceutical and biotechnology industries for more than three decades. In addition to Idera, Mr. Pien serves as the Non-executive Chairman of Indivior PLC. Previously Mr. Pien was the Lead Independent Director of ViroPharma Incorporated, Chairman of the Board of Vanda Pharmaceuticals and Chairman of the Board of Directors of Juno Therapeutics. Mr. Pien’s additional prior Board service includes Ikaria Inc., Immunogen, Inc. and Sage Therapeutics.
-Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors-. -Chief Financial Officer Louis J. Arcudi III departing the company related to company consolidation to Pennsylvania-. ...
Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that the company will participate in the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 2:10 p.m. Eastern Time at the St. Regis Hotel in New York City. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements.
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Portola Pharmaceuticals were deep in the red on Thursday after reporting second quarter results that revealed revenue and earnings miss. Idera Pharmaceuticals shares were rising after announcing that the company would be a part of a fireside chat in NYC next week. The company also reported second quarter results last week that revealed a positive earnings surprise.
Idera (IDRA) delivered earnings and revenue surprises of 26.25% and -9.44%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 59 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...